Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Proposes Unilateral Solution To Northern Ireland Medicines Supply Problems

UK Plans Special Contingency Measure

Executive Summary

The latest proposals for solving regulatory and trade issues caused by Brexit and the Northern Ireland Protocol have been welcomed by EU and UK pharmaceutical industry bodies.

You may also be interested in...



EU To Offer Solution To Post-Brexit Regulatory Problems In Northern Ireland

The EU is preparing a formal proposal for ensuring the continued long-term supply of medicines from Great Britain to Northern Ireland from next year, but it will require "enhanced enforcement" by the UK authorities.

UK Regulator Calls For More Patient Involvement In Trial Design

UK plans for a flexible and streamlined clinical trial regulatory regime are now out for consultation, covering areas such as investigational medicinal products, greater patient involvement in trial design, and lighter-touch oversight of low-intervention trials.

UK Kicks Off Landmark Overhaul Of Clinical Trial Framework

The UK regulatory agency, the MHRA, is planning to establish a “world-class sovereign regulatory environment” for clinical trials to support the development of new innovative medicines. In the first of two articles, we look at the MHRA’s proposals to slim down trial approval processes, lighten the safety reporting burden, and introduce greater transparency of trial registration and results.

Topics

UsernamePublicRestriction

Register

PS145429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel